Stay updated with breaking news from Lawrence Eichenfield. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lawrence Eichenfield, MD, of Rady Children's Hospital - San Diego, discusses the implications of the findings from INTEGUMENT-PED, the phase 3 study assessing the efficacy and safety of once-daily roflumilast cream 0.05% in pediatric patients with atopic dermatitis (AD).
-- Hubert Chen, accomplished drug developer and pharma executive, joins as Chief Medical Officer-- Industry veterans and leading academic experts ...
-- Hubert Chen, accomplished drug developer and pharma executive, joins as Chief Medical Officer
These findings, to be presented at AAAAI, may allow for greater awareness among clinicians when prescribing eczema therapies.
In this interview, Eichenfield discussed the recent pooled analysis from two phase 3 studies looking at once-daily, topical roflumilast for patients 6 and older with eczema.